《MedRxiv,4月3日,Using ILI surveillance to estimate state-specific case detection rates and forecast SARS-CoV-2 spread in the United States》

  • 来源专题:COVID-19科研动态监测
  • 编译者: xuwenwhlib
  • 发布时间:2020-04-05
  • Using ILI surveillance to estimate state-specific case detection rates and forecast SARS-CoV-2 spread in the United States

    View ORCID ProfileJustin D Silverman, View ORCID ProfileAlex D Washburne

    doi: https://doi.org/10.1101/2020.04.01.20050542

    This article is a preprint and has not been certified by peer review [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.

    Abstract

    Detection of SARS-CoV-2 infections to date has relied on RT-PCR testing. However, a failure to identify early cases imported to a country, bottlenecks in RT-PCR testing, and the existence of infections which are asymptomatic, sub-clinical, or with an alternative presentation than the standard cough and fever have resulted in an under-counting of the true prevalence of SARS-CoV-2. Here, we show how publicly available CDC influenza-like illness (ILI) outpatient surveillance data can be repurposed to estimate the detection rate of symptomatic SARS-CoV-2 infections. We find a surge of non-influenza ILI above the seasonal average and show that this surge is correlated with COVID case counts across states. By quantifying the number of excess ILI patients in March relative to previous years and comparing excess ILI to confirmed COVID case counts, we estimate the symptomatic case detection rate of SARS-CoV-2 in the US to be 1/100 to 1/1000. This corresponds to approximately 10 million presumed symptomatic SARS-CoV-2 patients across the US during the week starting on March 15, 2020. Combining excess ILI counts with the date of onset of community transmission in the US, we also show that the early epidemic in the US was unlikely to be doubling slower than every three days. Together these results suggest a conceptual model for the COVID epidemic in the US in which rapid spread across the US are combined with a large population of infected patients with presumably mild-to-moderate clinical symptoms. We emphasize the importance of testing these findings with seroprevalence data, and discuss the broader potential to repurpose outpatient time series for early detection and understanding of emerging infectious diseases.

  • 原文来源:https://www.medrxiv.org/content/10.1101/2020.04.01.20050542v1
相关报告
  • 《MedRxiv,5月3日,Enhanced Contact Investigations for Nine Early Travel-Related Cases of SARS-CoV-2 in the United States》

    • 来源专题:COVID-19科研动态监测
    • 编译者:xuwenwhlib
    • 发布时间:2020-05-04
    • Enhanced Contact Investigations for Nine Early Travel-Related Cases of SARS-CoV-2 in the United States View ORCID ProfileRachel M Burke, Sharon Balter, Emily Barnes, Vaughn Barry, Karri Bartlett, Karlyn D Beer, Isaac Benowitz, Holly M Biggs, Hollianne Bruce, Jonathan Bryant-Genevier, Jordan Cates, Kevin Chatham-Stephens, Nora Chea, Howard Chiou, Demian Christiansen, Victoria Chu, Shauna Clark, Sara H. Cody, Max Cohen, Erin E Conners, Vishal Dasari, Patrick Dawson, Traci DeSalvo, Matthew Donahue, Alissa Dratch, Lindsey Duca, Jeffrey Duchin, Jonathan W Dyal, Leora R Feldstein, Marty Fenstersheib, Marc Fischer, Rebecca Fisher, Chelsea Foo, Brandi Freeman-Ponder, Alicia M Fry, Jessica Gant, Romesh Gautom, Isaac Ghinai, Prabhu Gounder, Cheri T Grigg, Jeffrey Gunzenhauser, Aron J Hall, George S Han, Thomas Haupt, Michelle Holshue, Jennifer Hunter, Mireille B Ibrahim, Max W Jacobs, M. Claire Jarashow, Kiran Joshi, Talar Kamali, Vance Kawakami, Moon Kim, Hannah Kirking, Amanda Kita-Yarbro, Rachel Klos, Miwako Kobayashi, Anna Kocharian, Misty Lang, Jennifer Layden, Eva Leidman, Scott Lindquist, Stephen Lindstrom, Ruth Link-Gelles, Mariel Marlow, Claire P Mattison, Nancy McClung, Tristan McPherson, Lynn Mello, Claire M Midgley, Shannon Novosad, Megan T Patel, Kristen Pettrone, Satish K Pillai, Ian W Pray, Heather E Reese, Heather Rhodes, Susan Robinson, Melissa Rolfes, Janell Routh, Rachel Rubin, Sarah L Rudman, Denny Russell, Sarah Scott, Varun Shetty, Sarah E Smith-Jeffcoat, Elizabeth A Soda, Chris Spitters, Bryan Stierman, Rebecca Sunenshine, Dawn Terashita, Elizabeth Traub, Grace E Vahey, Jennifer R Verani, Megan Wallace, Matthew Westercamp, Jonathan Wortham, Amy Xie, Anna Yousaf, Matthew Zahn doi: https://doi.org/10.1101/2020.04.27.20081901 Abstract Background Coronavirus disease 2019 (COVID-19), the respiratory disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in Wuhan, China and has since become pandemic. As part of initial response activities in the United States, enhanced contact investigations were conducted to enable early identification and isolation of additional cases and to learn more about risk factors for transmission. Methods Close contacts of nine early travel-related cases in the United States were identified. Close contacts meeting criteria for active monitoring were followed, and selected individuals were targeted for collection of additional exposure details and respiratory samples. Respiratory samples were tested for SARS-CoV-2 by real-time reverse transcription polymerase chain reaction (RT-PCR) at the Centers for Disease Control and Prevention. Results There were 404 close contacts who underwent active monitoring in the response jurisdictions; 338 had at least basic exposure data, of whom 159 had at least 1 set of respiratory samples collected and tested. Across all known close contacts under monitoring, two additional cases were identified; both secondary cases were in spouses of travel-associated case patients. The secondary attack rate among household members, all of whom had at least 1 respiratory sample tested, was 13% (95% CI: 4 - 38%). Conclusions The enhanced contact tracing investigations undertaken around nine early travel-related cases of COVID-19 in the United States identified two cases of secondary transmission, both spouses. Rapid detection and isolation of the travel-associated case patients, enabled by public awareness of COVID-19 among travelers from China, may have mitigated transmission risk among close contacts of these cases.
  • 《4月3日_利用流感样疾病监测数据来重新估计美国各州的检出率并预测SARS-CoV-2在美国的传播情况》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-04-07
    • 1.时间:2020年4月3日 2.机构或团队:宾夕法尼亚州立大学、蒙大拿州立大学 3.事件概要: 4月3日,medRxiv预印本平台发表了来自宾夕法尼亚州立大学、蒙大拿州立大学研究团队题为“Using ILI surveillance to estimate state-specific case detection rates and forecast SARS-CoV-2 spread in the United States”的文章。 该文章认为SARS-CoV-2的检测以RT-PCR测试为主,囿于方法的局限性可能导致计算的感染率较低,该文章旨在利用可公开获得的CDC流感样疾病(ILI)门诊监测数据重新用于估计有症状SARS-CoV-2感染的检出率。该文章指出,非流感ILI的激增高于季节性平均值,并表明该激增与各州的COVID-19病例数相关。通过量化3月相对于往年3月的过量ILI患者数量,并将过量ILI与确诊的COVID-19病例数进行比较,该文章估计在美国,SARS-CoV-2的症状病例检出率为1/100至1/1000。这相当于从2020年3月15日开始的一周,全美大约1000万有症状的SARS-CoV-2症状患者。该文章指出,结合过量的ILI计数与美国社区传播的开始日期,美国的早期流行病不可能比每三天翻一倍慢,这些结果共同表明了一个美国COVID-19流行的概念模型。该文章强调使用血清阳性率数据测试这些发现的重要性,并讨论将门诊时间序列重新用于早期发现和了解新发传染病的广泛潜力。 *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用。 4.附件: 原文链接https://www.medrxiv.org/content/10.1101/2020.04.01.20050542v1